These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16816345)

  • 1. Natriuretic peptide measurements as part of the diagnostic work-up in pleural effusions: an emerging concept?
    Mueller T; Haltmayer M
    Eur Respir J; 2006 Jul; 28(1):7-9. PubMed ID: 16816345
    [No Abstract]   [Full Text] [Related]  

  • 2. High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions.
    Kolditz M; Halank M; Schiemanck CS; Schmeisser A; Höffken G
    Eur Respir J; 2006 Jul; 28(1):144-50. PubMed ID: 16481382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and pleural fluid N-Terminal-Pro-B-Type natriuretic peptide concentrations in the differential diagnosis of pleural effusions.
    Yorgancıoğlu A; Ozgen Alpaydın A; Yaman N; Taneli F; Bayturan O; Sakar Coşkun A; Celik P
    Tuberk Toraks; 2011; 59(1):1-7. PubMed ID: 21554224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tailored drug therapy in heart failure--a future vision. Biological markers can support individually directed treatment].
    Dahlström U
    Lakartidningen; 2009 Oct 14-20; 106(42):2674-5. PubMed ID: 19967945
    [No Abstract]   [Full Text] [Related]  

  • 5. Utilization of B-type natriuretic peptide and NT-proBNP in the diagnosis of pleural effusions due to heart failure.
    Porcel JM
    Curr Opin Pulm Med; 2011 Jul; 17(4):215-9. PubMed ID: 21415751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting.
    Green SM; Green JA; Januzzi JL
    Am J Ther; 2009; 16(2):171-7. PubMed ID: 19300043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unilateral Pleural Effusions with More Than One Apparent Etiology. A Prospective Observational Study.
    Bintcliffe OJ; Hooper CE; Rider IJ; Finn RS; Morley AJ; Zahan-Evans N; Harvey JE; Skyrme-Jones AP; Maskell NA
    Ann Am Thorac Soc; 2016 Jul; 13(7):1050-6. PubMed ID: 27064965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contra: Natriuretic peptides as diagnostic tool. Still obstacles for routine use in heart failure].
    Lindstedt G
    Lakartidningen; 2006 Mar 22-28; 103(12):930-2, 934-7. PubMed ID: 16618037
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pro: Natriuretic peptides as diagnostic tool. The analysis should be a routine in heart failure diagnosis].
    Dahlström U; Alehagen U
    Lakartidningen; 2006 Mar 22-28; 103(12):927-9. PubMed ID: 16618036
    [No Abstract]   [Full Text] [Related]  

  • 10. Can we IMPROVE-CHF management by measuring natriuretic peptides?
    Greenberg B
    Circulation; 2007 Jun; 115(24):3045-7. PubMed ID: 17576881
    [No Abstract]   [Full Text] [Related]  

  • 11. Natriuretic peptides in the diagnosis and management of acute heart failure.
    Mohammed AA; Januzzi JL
    Heart Fail Clin; 2009 Oct; 5(4):489-500. PubMed ID: 19631174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood biomarker measurement as disease target: the case for generic treatment of high natriuretic peptide levels without a diagnosis of heart failure.
    Clark AL
    J R Coll Physicians Edinb; 2013; 43(2):99-100. PubMed ID: 23734347
    [No Abstract]   [Full Text] [Related]  

  • 13. Are natriuretic peptides a reliable marker for mortality in ESRD patients?
    Locatelli F; Viganò S
    Nephrol Dial Transplant; 2010 Feb; 25(2):347-9. PubMed ID: 19934079
    [No Abstract]   [Full Text] [Related]  

  • 14. [Natriuretic peptides--new diagnostic markers in heart disease].
    Angermann CE; Ertl G
    Herz; 2004 Sep; 29(6):609-17. PubMed ID: 15912436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical utility of natriuretic peptdies in dyspnea].
    Müller C
    Ther Umsch; 2009 Sep; 66(9):649-52. PubMed ID: 19725009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of biomarkers for risk stratification in the tailored follow-up of heart failure patients].
    Aspromonte N; Di Tano G; Latini R; Masson S; Valle R; Emdin M
    G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 2):17S-23S. PubMed ID: 20873464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating natriuretic peptide levels in acute heart failure.
    Maisel A
    Rev Cardiovasc Med; 2007; 8 Suppl 5():S13-21. PubMed ID: 18192949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-type natriuretic peptide in heart failure.
    Moe GW
    Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CA-125 - does this next biomarker have a chance to hope for an expectation of risk stratification in patients with heart failure?].
    Zieliński T
    Kardiol Pol; 2010 Jul; 68(7):779-80. PubMed ID: 20648435
    [No Abstract]   [Full Text] [Related]  

  • 20. On "Getting the right message".
    Collins SP
    Ann Emerg Med; 2007 Mar; 49(3):383-4; author reply 384. PubMed ID: 17317514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.